Dear Editor,We thank Drs Rodr?guez and Anaya for their interest inour publication.1 We agree that the situation in Bangladesh2 seems to differ from the context of the ZIKV outbreaks in the Pacific Islands and Latin America.3 Theintroduction of ZIKV did not cause an apparent epidemicor increase the incidence of acute flaccid paralysis GBS inBangladesh. The only PCR-confirmed ZIKV infection inBangladesh was reported in 2014.4 We provided the firstdata on the seroprevalence of ZIKV-neutralizing antibodies in Bangladesh (0–13.2%). Although our study wasconducted during the period when ZIKV spread fromAsia and Africa to the Pacific islands and Latin America,no ZIKV-related disease outbreaks were reported in Bangladesh. Thus, it appears that the introduction and circulation of ZIKV is not necessarily followed by an increasein GBS. The determinants driving the emergence ofZIKV-related GBS are yet unknown.
展开▼
